HYPR (Hyperfine, Inc. Class A Common Stock) Stock Analysis - News
Hyperfine, Inc. Class A Common Stock (HYPR) is a publicly traded Healthcare sector company. As of May 21, 2026, HYPR trades at $1.49 with a market cap of $143.94M and a P/E ratio of -3.66. HYPR moved +5.67% today. Year to date, HYPR is +49.49%; over the trailing twelve months it is +137.83%. Its 52-week range spans $0.53 to $2.22. Analyst consensus is strong buy with an average price target of $2.17. Rallies surfaces HYPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in HYPR news today?
Hyperfine Benefits as FDA Registry Tops 1,200 AI Devices, Spurring Funding Surge: Hyperfine is highlighted among five firms building decentralized AI-powered cardiac diagnostics platforms, attracting the largest share of venture funding in the biopharmaceutical sector. The FDA registry now exceeds 1,200 approved AI medical devices, with cardiovascular applications as the second-largest category, providing a strong regulatory tailwind.
Hyperfine Benefits as FDA Registry Tops 1,200 AI Devices, Spurring Funding Surge: Hyperfine is highlighted among five firms building decentralized AI-powered cardiac diagnostics platforms, attracting the largest share of venture funding in the biopharmaceutical sector. The FDA registry now exceeds 1,200 approved AI medical devices, with cardiovascular applications as the second-largest category, providing a strong regulatory tailwind.
Does Rallies summarize HYPR news?
Yes. Rallies summarizes HYPR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is HYPR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HYPR. It does not provide personalized investment advice.
